MARKET

MBX

MBX

MBX Biosciences Inc
NASDAQ
60.04
-1.01
-1.65%
After Hours: 53.76 -6.28 -10.46% 17:42 07/13 EDT
OPEN
60.00
PREV CLOSE
61.05
HIGH
60.88
LOW
56.64
VOLUME
634.10K
TURNOVER
--
52 WEEK HIGH
66.55
52 WEEK LOW
9.63
MARKET CAP
2.86B
P/E (TTM)
-27.1908
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 5h ago
BUZZ-MBX Biosciences falls after executive shakeup
Reuters · 5h ago
MBX Biosciences appoints Steve Hoerter as CEO and John Smither as CFO
Seeking Alpha · 5h ago
MBX Biosciences CEO Kent Hawryluk steps down, Steve Hoerter succeeds
TipRanks · 5h ago
MBX Biosciences Appoints Steve Hoerter As Chairman And CEO, Succeeding Kent Hawryluk, With John Smither Named Interim CFO, Effective Immediately
Benzinga · 5h ago
*MBX Biosciences Names John Smither as New Chief Fincl Officer >MBX
Dow Jones · 6h ago
*MBX Biosciences: Hoerter Succeeds Kent Hawryluk, Who Will Step Down as Pres, CEO and Board Member
Dow Jones · 6h ago
*MBX Biosciences Names Exec Chairman Hoerter as New Chairman and CEO >MBX
Dow Jones · 6h ago
More
About MBX
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. It has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.

Webull offers MBX Biosciences, Inc. stock information, including NASDAQ: MBX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MBX stock methods without spending real money on the virtual paper trading platform.